Stock Track | ImmunityBio Soars on Positive Trial Update for Cancer Treatment-To The Moon - Tiger Brokers Online Investing Community - To The Moon

1
Comment
Favorite

Stock Track | ImmunityBio Soars on Positive Trial Update for Cancer Treatment

Stock Track10-25 23:16

Shares of ImmunityBio, Inc. (NASDAQ: IBRX) surged over 34% on Thursday, October 25, 2024, as the immunotherapy developer announced the initiation of dosing in a Phase 1 clinical trial for its novel CD19 t-haNK cell therapy.

The Phase 1 trial aims to evaluate the safety and preliminary efficacy of ImmunityBio's CD19 t-haNK cell therapy in patients with relapsed or refractory B-cell malignancies. This investigational therapy combines the company's proprietary natural killer (NK) cell platform with a chimeric antigen receptor (CAR) targeting the CD19 antigen, which is commonly expressed in various B-cell cancers.

The positive development concerning ImmunityBio's cancer treatment pipeline appears to be driving the significant stock price increase, as investors anticipate the potential success of the company's innovative immunotherapy approach. The company's focus on developing cutting-edge cellular therapies for various cancers has garnered significant interest from the biotech investment community.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

1

Report

Comment

empty

No comments yet

Most Discussed

7x24

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1143011088?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-25 23:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1143011088","market":"hk","top_or_hot":-1,"title":"Stock Track | ImmunityBio Soars on Positive Trial Update for Cancer Treatment","media":"Stock Track","content":"<p>Shares of ImmunityBio, Inc. (NASDAQ: IBRX) surged over 34% on Thursday, October 25, 2024, as the immunotherapy developer announced the initiation of dosing in a Phase 1 clinical trial for its novel CD19 t-haNK cell therapy.</p>\n\n<p>The Phase 1 trial aims to evaluate the safety and preliminary efficacy of ImmunityBio's CD19 t-haNK cell therapy in patients with relapsed or refractory B-cell malignancies. This investigational therapy combines the company's proprietary natural killer (NK) cell platform with a chimeric antigen receptor (CAR) targeting the CD19 antigen, which is commonly expressed in various B-cell cancers.</p>\n\n<p>The positive development concerning ImmunityBio's cancer treatment pipeline appears to be driving the significant stock price increase, as investors anticipate the potential success of the company's innovative immunotherapy approach. The company's focus on developing cutting-edge cellular therapies for various cancers has garnered significant interest from the biotech investment community.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | ImmunityBio Soars on Positive Trial Update for Cancer Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | ImmunityBio Soars on Positive Trial Update for Cancer Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n2024-10-25 23:16 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of ImmunityBio, Inc. (NASDAQ: IBRX) surged over 34% on Thursday, October 25, 2024, as the immunotherapy developer announced the initiation of dosing in a Phase 1 clinical trial for its novel ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IBRX","symbol_name":"ImmunityBio, Inc.","start_time":0,"source_url":"","article_id":"1143011088","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1143011088","pubTimestamp":1729869384,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of ImmunityBio, Inc.  surged over 34% on Thursday, October 25, 2024, as the immunotherapy developer announced the initiation of dosing in a Phase 1 clinical trial for its novel CD19 t-haNK cell therapy.The Phase 1 trial aims to evaluate the safety and preliminary efficacy of ImmunityBio's CD19 t-haNK cell therapy in patients with relapsed or refractory B-cell malignancies. This investigational therapy combines the company's proprietary natural killer  cell platform with a chimeric antigen","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IBRX":"ImmunityBio, Inc."},"translate_title":"股票追踪ImmunityBio因癌症治疗试验更新积极而飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBRX":1},"content_text":"Shares of ImmunityBio, Inc. (NASDAQ: IBRX) surged over 34% on Thursday, October 25, 2024, as the immunotherapy developer announced the initiation of dosing in a Phase 1 clinical trial for its novel CD19 t-haNK cell therapy.\nThe Phase 1 trial aims to evaluate the safety and preliminary efficacy of ImmunityBio's CD19 t-haNK cell therapy in patients with relapsed or refractory B-cell malignancies. This investigational therapy combines the company's proprietary natural killer (NK) cell platform with a chimeric antigen receptor (CAR) targeting the CD19 antigen, which is commonly expressed in various B-cell cancers.\nThe positive development concerning ImmunityBio's cancer treatment pipeline appears to be driving the significant stock price increase, as investors anticipate the potential success of the company's innovative immunotherapy approach. The company's focus on developing cutting-edge cellular therapies for various cancers has garnered significant interest from the biotech investment community.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}